The Seattle Times: Biotech News Archive
http://seattletimes.nwsource.com/rss/biotech.xml
Page: 1 of 1
- Wall Street biotech insider gets No. 2 job at the FDA
- Bianco survives bid to oust him as biotech CEO
- Creating life from scratch, one molecule at a time
- Merck found liable in nation's first Vioxx trial
- 2 biotechs excel, buoy investors
- Mutant mice invaluable tool for researchers
- Bicoastal battle for biotech: Universities vying for research dollars
- Biotech companies scramble to develop brain-related products
- Genetech halts trial of drug
- Viagra may be unintended wildlife conservation tool, study finds
- Sonus drug lures Schering
- Bristol-Myers may scrap key diabetes drug, end collaboration with Merck
- Targeted Genetics receives NIH grant
- Biotech spinoff planned
- 34 jobs cut as Dendreon focuses on FDA filing
- Seattle biotech Dendreon cuts 15 percent of staff
- Targeted Genetics cuts one-fourth of staff
- Amgen to boost business, add 150 jobs in Seattle
- Icos posts first quarterly profit
- Northstar Neuroscience IPO seeks $85 million
- Race intense for drug to slow Alzheimer's
- Cell Therapeutics discloses probe info
- Biotech upsets just about everybody with its diarrhea treatment
- ZymoGenetics fills clinical trial slots
- Alder BioPharmaceuticals raises $16 million in second round of funding
- Nastech drug gets rejection from FDA
- Corus Pharma sold for $365 million
- Using ultrasound for war wounds
- Cell Therapeutics raises $40 million in stock sale
- Frazier Healthcare brings in experts
- Cell CEO sells shares day before stock takes a big dive
- Cell CEO sells stocks before big dive; company says trade was automatic
- Trubion shares dip after IPO
- Icos sale to enrich top executives
- Key Icos investor opposes sale, says share price is too low